Compounded Semaglutide vs Wegovy/Ozempic: What Is and Isn't Different
What compounded semaglutide is
Compounded semaglutide is a pharmaceutical preparation of the same active ingredient (semaglutide) as Wegovy and Ozempic, produced by a compounding pharmacy under §503A or §503B exemptions of the Federal Food, Drug, and Cosmetic Act.
Compounding pharmacies are permitted to prepare drugs that are not otherwise commercially available or that are customised for specific patients — but during a period of FDA-declared shortage (which applied to semaglutide from 2022 to early 2025), they were also permitted to compound copies of drugs that were on the shortage list.
The key regulatory difference: Branded Wegovy and Ozempic are FDA-approved, meaning they have undergone rigorous manufacturing standards review, bioequivalence testing, and ongoing FDA manufacturing oversight. Compounded semaglutide is not FDA-approved — the compounding pharmacy is responsible for quality, but does not undergo the same regulatory scrutiny as a pharmaceutical manufacturer.
The active ingredient: what is the same
The active molecule in both branded and compounded semaglutide is semaglutide — a 34-amino-acid peptide that is a modified analogue of human GLP-1. The mechanism of action is identical.
When a patient takes a correctly-dosed, correctly-formulated preparation of semaglutide from a compounding pharmacy, the therapeutic effect should be equivalent to Wegovy or Ozempic at the same dose.
The pharmacological distinction between branded and compounded semaglutide is not the active molecule. It is the manufacturing environment, quality assurance, and regulatory oversight.
What is different: manufacturing and quality
Novo Nordisk manufacturing (branded)
- GMP (good manufacturing practice) facilities with FDA oversight
- Rigorous quality control at every batch: potency, purity, sterility testing
- Established stability data across storage conditions
- FDA-approved formulation (excipients, pH, preservatives) validated for subcutaneous injection
Compounding pharmacy manufacturing
- Must follow USP (US Pharmacopeia) compounding standards for sterile preparations
- 503A pharmacies serve individual patients with a prescription; 503B pharmacies manufacture larger volumes for clinical use
- Quality testing requirements exist but are less comprehensive than FDA drug approval standards
- No FDA review of the specific formulation
- Stability data is based on referenced literature and in-house testing, not FDA-reviewed studies
What this means in practice: Most accredited compounding pharmacies produce safe, effective compounded semaglutide. The risk is not that compounding pharmacies are generally unsafe — most are not. The risk is that quality varies between pharmacies, and the oversight system to catch quality failures is less comprehensive than the FDA drug approval system.
The FDA issued warnings about specific compounded semaglutide products that were found to contain:
- Incorrect concentration (under-dosing or overdosing risk)
- Incorrect inactive ingredients
- Bacterial contamination in non-sterile preparation facilities
These failures occurred at a small number of pharmacies, not across the category, but they illustrate the real quality gap.
The salt vs base formulation issue
A significant controversy in the compounded semaglutide space involves the form of semaglutide used.
Branded Wegovy and Ozempic use semaglutide free base — the pure active molecule form.
Some compounding pharmacies use semaglutide sodium or semaglutide acetate (salt forms) rather than the free base. The FDA has issued specific warnings that semaglutide salts are not the same as semaglutide free base — they have not been shown to be bioequivalent and should not be substituted.
How to check: Ask your compounding pharmacy specifically whether they use semaglutide free base or a salt form. Reputable pharmacies use the base form. Pharmacies using salt forms either knowingly or unknowingly may be providing a subtherapeutic or non-equivalent product.
Price comparison
This is where compounded semaglutide wins substantially:
| Branded (Wegovy) | Compounded semaglutide | |
|---|---|---|
| List price (full dose) | ~$1,350/month | $150–$350/month |
| With savings programme | ~$499/month | N/A (no manufacturer programme) |
| With commercial insurance | $25–75/month (if covered) | Not covered by insurance |
| Cash pay, no assistance | ~$1,350/month | $150–$350/month |
For the approximately 70–75% of patients who do not have insurance coverage for Wegovy, compounded semaglutide offers a 70–80% cost reduction at cash prices. For a full breakdown of branded costs and assistance programmes, see Wegovy without insurance.
The regulatory picture as of 2025
In early 2025, the FDA declared the semaglutide shortage resolved (Novo Nordisk certified adequate supply). This had a significant consequence: 503A pharmacies could no longer legally compound copies of branded semaglutide for individual patients once the shortage ended.
The practical situation as of mid-2025:
- 503A pharmacy compounding of semaglutide is legally permitted only for patients with a documented, specific clinical need that the branded product cannot meet (documented allergy to a branded excipient, for example)
- 503B outsourcing facilities were given additional time before restrictions applied
- The FDA began enforcement actions against some 503A pharmacies continuing to compound without qualifying exemption
Patients using compounded semaglutide from a §503A pharmacy after the shortage resolution should be aware that:
- The legal basis for the compounding may have changed
- Their pharmacy may be operating in a legally grey area
- FDA enforcement actions could disrupt supply
For a detailed current status on specific providers, see our regulatory tracking articles on 503A vs 503B compounding.
Who compounded semaglutide is appropriate for
The access question: for a patient who genuinely cannot afford branded semaglutide, or cannot obtain insurance coverage, is compounded semaglutide from a reputable pharmacy better than no semaglutide?
From a public health perspective, the answer for many patients is yes. The therapeutic benefits of semaglutide for obesity, T2D, and cardiovascular risk reduction are substantial and evidence-based. Denying these benefits because the only affordable option is compounded involves trading a modest quality/regulatory risk for a large health outcome risk.
The appropriate filter is pharmacy quality — not "compounded vs branded" in binary terms. Compounded from an accredited, reputable pharmacy is meaningfully different from compounded from an unaccredited internet pharmacy.
Pharmacy quality signals
- PCAB (Pharmacy Compounding Accreditation Board) accreditation
- Proof of sterility testing on each batch
- COA (Certificate of Analysis) available on request
- Clear formulation disclosure (semaglutide free base, concentration, excipients)
- US-based pharmacy with verifiable address and state pharmacy board registration
Summary
Compounded semaglutide and branded Wegovy/Ozempic contain the same active molecule. Compounded versions cost 70–85% less at cash pay. For the tirzepatide equivalent, see compounded vs brand tirzepatide. To start the prescribing process, see how to get a GLP-1 prescription. The differences are manufacturing oversight (branded = FDA-reviewed; compounded = pharmacy-responsible), regulatory status (branded = approved; compounded = exempted), and formulation verification (some compounders use non-equivalent salt forms). Reputable accredited compounding pharmacies generally produce safe product; quality assurance varies significantly across the market. The legal basis for semaglutide compounding changed in early 2025 when the FDA shortage designation was lifted.